Extended observation of reduced methamphetamine use with combined naltrexone plus bupropion in the ADAPT-2 trial.

Michael J LiBrendon ChauThomas BelinThomas CarmodyManish K JhaElise N MarinoMadhukar H Trivedi Steven J Shoptaw

Published in: Addiction (Abingdon, England) (2024)

For people with methamphetamine (MA) use disorder receiving treatment with extended-release injectable naltrexone plus extended-release oral bupropion (NTX + BUPN), continued treatment with NTX + BUPN after 6 weeks is associated with additional reductions in MA use up to 12 weeks.

Keyphrases

study protocol
phase iii
hyaluronic acid
preterm birth
placebo controlled